Epitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />CAMBRIDGE, UK and MONTREAL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed in OVACT, its...